NSE: PPLPHARMA | BSE: 543635

Momentum Trap

Download real time

210.53 5.80 (2.83%)

Near 52W High of ₹218.50

5.7M NSE+BSE Volume

NSE 18 Aug, 2026 3:31 PM (IST)

28,028.9

Market Cap

High in industry

Beta 1Year

High Volatility

Piramal Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PPLPHARMA, BSE:543635 Piramal Pharma Ltd.

Search Inside the pdf :

Piramal Pharma Ltd.

31 Jul 2026

210.53

2.83%

Entering next growth orbit

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma (Piramal)’s upbeat performance in Q1FY27 (revenue up 17.4%) stemmed from solid traction across segments (+15–19%) and currency benefit; thus, enabling a 308bps expansion in EBITDA margins to 8.6%.

Piramal Pharma Ltd. has an average target of 238.33 from 3 brokers.

Piramal Pharma Ltd.

30 Jul 2026

210.53

2.83%

Broad-based growth drives improved operational performance

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected revenue/EBITDA (7%/41% beat) for 1QFY27. The company also reported a lower-than-expected loss, supported by higher other income.

Number of FII/FPI investors increased from 231 to 239 in Jun 2026 qtr.

Piramal Pharma Ltd.

30 Jul 2026

210.53

2.83%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

: Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates in 3 major segments. Contract development and manufacturing organisations (CDMO) Complex hospital generics (critical care)...

Number of FII/FPI investors increased from 231 to 239 in Jun 2026 qtr.

Piramal Pharma Ltd.

30 Apr 2026

210.53

2.83%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

Normalisation expected from FY27- Overall performance was largely in line with expectations. The CDMO business was impacted by de-stocking; adjusting for this, the segment delivered healthy double-digit revenue growth in Q4. Improving biopharma funding is also translating into stronger RFP momentum and a pickup in order inflows for the CDMO segment. Management is also focusing on Cost Optimization & Operational Excellence which should help improve profitability of the segment going forward. The CHG business was affected by the postponement of certain...

Piramal Pharma Ltd. is trading above all available SMAs

Piramal Pharma Ltd.

29 Apr 2026

210.53

2.83%

Operationally below est.; ends FY26 on a weak note

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) posted in-line revenue for 4QFY26. The EBITDA was lower than expected (an 8% miss), primarily due to a product mix change.

FII/FPI have decreased holdings from 30.17% to 12.51% in Jun 2026 qtr

Piramal Pharma Ltd.

30 Jan 2026

210.53

2.83%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with...

Piramal Pharma has gained 17.34% in the last 1 Month

Piramal Pharma Ltd.

29 Jan 2026

210.53

2.83%

3Q below estimates; trough phase extends

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma posted a miss on revenue/EBITDA in 3QFY26, affected by low traction in CDMO business. Complex hospital generics (CHG) business was largely stable YoY, with regulatory delays keeping growth in check.

Piramal Pharma has gained 26.79% in the last 6 Months

Piramal Pharma Ltd.

06 Nov 2025

210.53

2.83%

2Q – A miss; higher opex drags earnings

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line revenue for 2QFY62. However, it delivered a miss on EBITDA/PAT for the quarter. Higher operational costs impacted the quarter’s performance.

Number of FII/FPI investors increased from 231 to 239 in Jun 2026 qtr.

Piramal Pharma Ltd.

29 Jul 2025

210.53

2.83%

Near-term weak due to the muted CHG business

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) exhibited lower-than-expected financial performance in 1QFY26. Lower CDMO and complex hospital generics (CHG) sales led to a considerable operating deleverage.

Piramal Pharma Ltd. is trading above all available SMAs

Piramal Pharma Ltd.

29 Jul 2025

210.53

2.83%

Temporary slowdown before a sprint

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).

FII/FPI have decreased holdings from 30.17% to 12.51% in Jun 2026 qtr

VOTE: Is Piramal Pharma Ltd. worth buying?

408 Votes:

Buy 83.09%

Sell 10.78%

Hold 6.13%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf